布地奈德使用说明

It is an inhaled glucocorticoid with strong anti-allergic inflammation effect, and its anti-allergic inflammation effect is weaker than fluticasone propionate and mometasone furoate. Budesonide has slightly poor fat solubility, but has a strong affinity for glucocorticoid receptors. This is mainly related to the special molecular configuration of budesonide. At the same time, because budesonide has a high first-pass metabolism effect in the liver (about 90%), the amount of drug entering the systemic circulation is significantly reduced. The above characteristics determine that budesonide has strong local anti-allergic inflammatory effects and fewer systemic side effects, making it more suitable for children. Studies have shown that budesonide’s airway anti-inflammatory strength is 600 times that of hydrocortisone and 0-30 times that of dexamethasone. In addition, inhaled budesonide has a strong local effect and is less absorbed. Inhaling smaller doses of budesonide has fewer side effects.

Recommended dosage of budesonide for the treatment of mild to moderately active Crohn's disease: Adults: 9 mg daily for up to 8 weeks; repeat 8-week course of treatment with recurrent episodes of active disease. Pediatrics 8 to 17 years weighing more than 25 kg: 9 mg once daily for up to 8 weeks, then 6 mg once daily for 2 weeks.

Budesonide dosage to maintain clinical remission in mild to moderate Crohn's disease: Adults: 6 mg daily for up to 3 months; discontinue after 3 months of completion of tapering. Continuation of treatment beyond 3 months has not been shown to provide substantial clinical benefit. When switching from oral prednisolone, begin tapering the prednisolone dose and simultaneously initiate budesonide.

Maintenance dose. When the clinical effect has been achieved, the dose should be gradually reduced to the lowest dose that can control symptoms. The medication should be taken twice a day, once in the morning and once in the evening. In clinical studies, no increase in the incidence of adverse reactions was seen when other commonly used drugs used to treat asthma were given concurrently. Ketoconazole, a potent inhibitor of cytochrome P450 3A, can increase the plasma concentration of budesonide and should be monitored clinically.